Ask your doctor about GLUMETZA
GLUMETZA is a type 2 diabetes medication that may help you effectively manage your diabetes. Learn more about the advanced technology behind this type 2 diabetes medicine.
Indication for GLUMETZA
GLUMETZA® (metformin hydrochloride extended-release tablets) is a prescription medicine that contains metformin hydrochloride used with diet and exercise to help control high blood sugar in adults with type 2 diabetes. GLUMETZA is not for people with type 1 diabetes. GLUMETZA is not for people with diabetic ketoacidosis (increased ketones in your blood or urine).
Important Safety Information about GLUMETZA
Do not take GLUMETZA® (metformin hydrochloride extended-release tablets) if you:
- have kidney problems
- are allergic to the metformin hydrochloride in GLUMETZA or any of the ingredients in GLUMETZA.
- are going to get an injection of dye or contrast agents for an x-ray procedure, GLUMETZA will need to be stopped for a short time. Talk to your doctor about when you should stop GLUMETZA and when you should start GLUMETZA again.
- have a condition called metabolic acidosis or diabetic ketoacidosis (increased ketones in your blood or urine).
Tell your healthcare provider if you drink alcohol very often, or drink a lot of alcohol in short-term.
Tell your healthcare provider if you are scheduled to have any tests that use radiocontrast or an injected dye or if you are having any surgical procedure that requires you to restrict your intake of food or liquids.
Your doctor should do blood tests to check how well your kidneys and liver are working before and during your treatment with GLUMETZA.
Tell your healthcare provider if you have problems with your liver. GLUMETZA may decrease your levels of Vitamin B12. Your doctor should monitor your blood levels on a yearly basis.
Tell your healthcare provider if you are taking insulin, or any of the following drugs as GLUMETZA may not be the right choice for you: amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin.
Safety and effectiveness in children younger than 18 years of age have not been established.
There have been no clinical studies that have been able to conclude a beneficial effect of GLUMETZA or any other oral anti-diabetic drug on reducing cardiovascular outcomes.
The most common adverse reactions (>5% of GLUMETZA-treated patients and at a rate greater than placebo) were low blood sugar (hypoglycemia). Symptoms of low blood sugar include: shaking, sweating, rapid heartbeat, change in vision, hunger, headache and change in mood. Other common adverse reactions include diarrhea, nausea, and upset stomach or stomach pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch/ or call 1-800-FDA-1088.
For product information, adverse event reports, and product complaint reports, please contact:
Salix Product Information Call Center